Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
GLP-1s and Obesity Coverage: Differing Perspectives for Employers and Health Plans Posted on August 21, 2025 A Snippet From Our GLP-1 Spotlight Webinar Key Points Employers tend to view obesity as a chronic condition, while health plans lean slightly toward viewing obesity as a lifestyle condition
A survey
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease (FLOW)
Get Started Schedule a consultation with our medical team to learn which tirzepatide formulation is right for your health goals
(The UK Medicines regulator (MHRA) has confirmed in its 2026 recommendation that the only person making fluid transition through the spectrum of GLP-1 medicines will be your prescriber.) Mounjaro to Wegovy Dose Conversion: What the Evidence Says It lacks a peer-reviewed conversion guide to refer to specifically because there have been no direct clinical trials comparing Mounjaro doses to Wegovy doses in a switching context
